Immunogenicity and Safety of Biological E’s 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14 ® ) Administered in a 2p+1 Schedule to Healthy Infants: A Multicenter, Randomized, Active Controlled, Single-Blind, Phase III Trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Pneumococcal conjugate vaccines (PCVs) have markedly reduced childhood pneumococcal diseases, yet serotype replacement and regional heterogeneity remain important challenges. The World Health Organization recommends either a 3p + 0 or 2p + 1 schedule for PCV immunization programmes. BE-PCV14, a 14-valent vaccine, has previously been shown to be non-inferior to PCV13 in a 3p + 0 regimen. In this study, we descriptively compared the immunogenicity and safety of BE-PCV14 and PCV13 in a 2p + 1 schedule in Indian infants.
Methods
In this randomized, single-blind, multicenter trial, 400 PCV-naïve infants (6–8 weeks old) were randomized 1:1 to receive either BE-PCV14 or PCV13; at 6 and 14 weeks, with a booster at 9 months. Serum IgGs against 14 vaccine serotypes plus cross-protective 6A were measured at post primary (28 days post dose 2), pre booster (at 9 months) and post booster (30 days post dose 3) time points. The primary endpoint was the proportion achieving IgG ≥ 0.35 µg/mL (seroconversion rate) for the 12 serotypes common to both vaccines at post primary, pre booster and post booster time points. Solicited local and systemic reactions were recorded for 7 days after each dose; unsolicited, medically attended, and serious adverse events (SAEs) were captured throughout.
Results
Between May 2023 to July 2024, 400 participants were enrolled of which 380 (95%) completed the study. Post primary seroconversion rates in the BE-PCV14 arm for common serotypes ranged from 72.6% (serotype 3) to 100% (14, 19F); PCV13 rates ranged from 71.6% to 100% (3 to 14, 19F, 19A). Post booster rates were 87.6–100% for BE-PCV14 and 85.0–100% for PCV13. BE-PCV14 elicited high responses against the two additional serotypes (22F: 96.8%; 33F: 95.3%) and cross-protective 6A (93.0%). Seroconversion rates and Geometric mean concentrations were similar between groups. Most adverse events were mild or moderate; two unrelated SAEs occurred in the BE-PCV14 arm.
Interpretation
Administered in a 2p + 1 schedule, BE-PCV14 was highly immunogenic, well tolerated, and comparable to PCV13 while broadening serotype coverage, supporting its inclusion in routine infant immunisation programmes.
Clinical Trials Registry of India Number: CTRI/2022/11/047366
